IP Library Granted Patent US 8,697,721
Granted Patent B2
US 8,697,721 · App. 13/319,955 · Granted Apr 15, 2014

Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Inventors: Dan Peters (Malmö, SE); Elsebet Østergaard Nielsen (København K, DK); Karin Sandager Nielsen (Fredensborg, DK); Gordon Munro (Skovlunde, DK)
Assignee: Aniona APS
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,697,721
App. No.
13/319,955
Granted
Apr 15, 2014
Kind
B2
Abstract

The present applications discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. In other aspects the applications discloses the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

Claims (7)

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein R 1 represents hydrogen.

2. The compound according to claim 1 , which is exo-7-[(8-Aza-bicyclo[3.2.1]oct-3-yl)oxy]-3-methyl-chromen-2-one hydrochloric acid salt.

3. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

4. A compound according to one of claims 1 or 2 , or a pharmaceutically acceptable salt thereof, for use as a medicament.

5. A method for treatment or alleviation of a disease or a disorder or a condition responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, wherein said disease, disorder, or condition is selected from the group consisting of mood disorder, depression, atypical depression, or attention deficit hyperactivity disorder (ADHD), which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to one of claims 1 or 2 , or a pharmaceutically acceptable salt thereof.

6. A method for treatment or alleviation of a disease or a disorder or a condition responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, wherein said disease, disorder, or condition is pain, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to one of claims 1 or 2 , or a pharmaceutically acceptable salt thereof.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2021
From: INITIATOR PHARMA A/S
To: INITIATOR PHARMA A/S
Reel/Frame 057545/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2017
From: SANIONA A/S
To: INITIATOR PHARMA A/S
Reel/Frame 041749/0065 →
CHANGE OF NAME Recorded Mar 27, 2017
From: ANIONA APS
To: SANIONA A/S
Reel/Frame 042098/0064 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2013
From: NEUROSEARCH A/S
To: ANIONA APS
Reel/Frame 030049/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2011
From: PETERS, DAN; NIELSEN, ELSEBET OSTERGAARD; NIELSEN, KARIN SANDAGER; MUNRO, GORDON
To: NEUROSEARCH A/S
Reel/Frame 027426/0460 →
Priority Claims (1)
DK PA 2009 00063 · May 15, 2009 · national
Continuity (2)
Provisional Application 61179986 · May 20, 2009
Related Publication 20120088789A1 · Apr 12, 2012